Treace Medical Concepts, Inc. (TMCI) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St rises with earnings in focus; PayPal jumps on takeover bid report
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
Treace Medical Concepts Reports Second Quarter 2023 Financial Results
August 8, 2023 4:05 PM EDTPONTE VEDRA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction Procedure, today reported financial results for the second quarter ended June 30, 2023.
Recent Highlights:
Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last yearBlended average revenue per Lapiplasty®... More